Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Middle East Conflict Impacts Australia and New Zealand Businesses 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
LAWRENCEVILLE, N.J., May 04, 2018 -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March 31, 2018 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. EDT on Friday, May 11, 2018. To participate in the call, interested parties may dial 1-888-298-3457 (Toll-Free/North America) or 1-719-325-4917 (International/Toll) and ask for the Celsion Corporation 1st Quarter 2018 Earnings Call (Conference Code: 6550185) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live over the internet at www.celsion.com.
The call will be archived for replay on Friday, May 11, 2018 and will remain available until Friday, May 25, 2018. The replay can be accessed at 1-888-203-1112 (Toll-Free/USA) or 1-719-457-0820 (International/Toll) using Conference ID: 6550185. An audio replay of the call will also be available on the Company’s website, www.celsion.com, for 90 days after 2:00 p.m. EDT on Friday, May 11, 2018.
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in development for other cancer indications. The Company’s product pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: http://www.celsion.com. (CLSN-FIN).
Celsion Investor Contact Jeffrey W. Church Sr. Vice President and CFO 609-482-2455 [email protected]
